Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS4 | P49798 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469706 | 0.88 | RGS4 (0.50) | RGS4MGLLPTGS1PTGS2FAAH | |
| SCHEMBL4855647 | 0.83 | RGS4 (0.41) | RGS4MGLLPTGS1PTGS2FAAH | |
| SCHEMBL3470129 | 0.79 | RGS4 (0.53) | RGS4MGLLCNR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27504237 | 0.78 | MGLL (0.47) | MGLLPTGS1PTGS2FAAHSMN1; SMN2 | |
| SCHEMBL7761775 | 0.78 | MGLL (0.47) | MGLLPTGS1PTGS2FAAHSMN1; SMN2 | |
| SCHEMBL18942761 | 0.78 | RGS4 (0.45) | RGS4MGLLPTGS1PTGS2FAAH | |
| SCHEMBL19886759 | 0.77 | MGLL (0.46) | MGLLPTGS1PTGS2FAAHSMN1; SMN2 | |
| SCHEMBL16285211 | 0.76 | PTGS1 (0.42) | RGS4MGLLPTGS1PTGS2FAAH | |
| SCHEMBL4852057 | 0.76 | RGS4 (0.50) | RGS4SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4850588 | 0.76 | RGS4 (0.46) | RGS4MGLLSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378419-B2 | 9-amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | LES LABORATOIRES SERVIER (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1664055-B9 | 9-AMINO-PODOPHYLLOTOXIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SERVIER LAB (FR) | 2007-10-10 | — | — | EP | disclosed |
| EP-1664055-B1 | 9-AMINO-PODOPHYLLOTOXIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SERVIER LAB (FR) | 2006-12-13 | — | — | EP | disclosed |
| US-20060247246-A1 | 9-Amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247246-A1 | 9-Amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | SIK2, PTK2B, PLK2 | RGS4 3547/4885MGLL 2313/4885PTGS1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.